Halozyme Therapeutics Inc (HALO)

[XenaLives]

First of all, the angst over pricing issues was over hyped IMO, in order to assist with the biotech dump. Long term pricing will still be an issue for biotechs because if Colorado's single payer healthcare program goes through and it's successful more states will follow suit.

Insurance companies allow high prices in the U.S. because what they keep is a function of payouts. More single payer systems in the U.S. means the biotech business model has to change and reimbursement will be more uniform world wide.

There is no excuse for the fact that the U.S. has the highest health care costs and the lowest quality in developed countries. Quality being evaluated by the care given to the population as a whole (lower survival rates in cancer and other serious disease being linked to economic class).